TITLE

Ticagrelor approved for acute coronary syndrome

AUTHOR(S)
Traynor, Kate
PUB. DATE
September 2011
SOURCE
American Journal of Health-System Pharmacy;9/1/2011, Vol. 68 Issue 17, p1568
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports the FDA approval of AstraZeneca's ticagrelor oral tablets, to be marketed as Brilinta. Ticagrelor, an antiplatelet agent, has been approved in conjunction with aspirin, for reducing the risk of heart attack and cardiovascular-related death in acute coronary syndrome patients. The article also offers information on the drug's dosage, contraindications, labeling and storage.
ACCESSION #
65535824

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics